PHILADELPHIA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference in New York, NY.
The event will take place at 1:30 p.m. ET on Thursday, September 10, 2015 at the Millennium Broadway Hotel. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: http://wsw.com/webcast/biocentury/mdgn.
About Medgenics, Inc.
Medgenics is developing the TARGT™ (Transduced Autologous Restorative Gene Therapy) system, a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com.